FDA Clears First Companion Diagnostic for Prostate Cancer Treatment

The FDA has approved Roche's Ventana PTEN RxDx Assay, a novel immunohistochemistry test designed to detect PTEN protein loss in prostate adenocarcinoma. This approval enables clinicians to identify prostate cancer patients who are most likely to benefit from a specific targeted therapy combination.